Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients: the multinational AID-ICU inception cohort study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients : the multinational AID-ICU inception cohort study. / Collet, Marie O; Caballero, Jesús; Sonneville, Romain; Bozza, Fernando A; Nydahl, Peter; Schandl, Anna; Wøien, Hilden; Citerio, Giuseppe; van den Boogaard, Mark; Hästbacka, Johanna; Haenggi, Matthias; Colpaert, Kirsten; Rose, Louise; Barbateskovic, Marija; Lange, Theis; Jensen, Aksel; Krog, Martin B; Egerod, Ingrid; Nibro, Helle L; Wetterslev, Jørn; Perner, Anders; AID-ICU cohort study co-authors.
In: Intensive Care Medicine, Vol. 44, No. 7, 2018, p. 1081-1089.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients
T2 - the multinational AID-ICU inception cohort study
AU - Collet, Marie O
AU - Caballero, Jesús
AU - Sonneville, Romain
AU - Bozza, Fernando A
AU - Nydahl, Peter
AU - Schandl, Anna
AU - Wøien, Hilden
AU - Citerio, Giuseppe
AU - van den Boogaard, Mark
AU - Hästbacka, Johanna
AU - Haenggi, Matthias
AU - Colpaert, Kirsten
AU - Rose, Louise
AU - Barbateskovic, Marija
AU - Lange, Theis
AU - Jensen, Aksel
AU - Krog, Martin B
AU - Egerod, Ingrid
AU - Nibro, Helle L
AU - Wetterslev, Jørn
AU - Perner, Anders
AU - AID-ICU cohort study co-authors
PY - 2018
Y1 - 2018
N2 - PURPOSE: We assessed the prevalence and variables associated with haloperidol use for delirium in ICU patients and explored any associations of haloperidol use with 90-day mortality.METHODS: All acutely admitted, adult ICU patients were screened during a 2-week inception period. We followed the patient throughout their ICU stay and assessed 90-day mortality. We assessed patients and their variables in the first 24 and 72 h in ICU and studied their association together with that of ICU characteristics with haloperidol use.RESULTS: We included 1260 patients from 99 ICUs in 13 countries. Delirium occurred in 314/1260 patients [25% (95% confidence interval 23-27)] of whom 145 received haloperidol [46% (41-52)]. Other interventions for delirium were benzodiazepines in 36% (31-42), dexmedetomidine in 21% (17-26), quetiapine in 19% (14-23) and olanzapine in 9% (6-12) of the patients with delirium. In the first 24 h in the ICU, all subtypes of delirium [hyperactive, adjusted odds ratio (aOR) 29.7 (12.9-74.5); mixed 10.0 (5.0-20.2); hypoactive 3.0 (1.2-6.7)] and circulatory support 2.7 (1.7-4.3) were associated with haloperidol use. At 72 h after ICU admission, circulatory support remained associated with subsequent use of haloperidol, aOR 2.6 (1.1-6.9). Haloperidol use within 0-24 h and within 0-72 h of ICU admission was not associated with 90-day mortality [aOR 1.2 (0.5-2.5); p = 0.66] and [aOR 1.9 (1.0-3.9); p = 0.07], respectively.CONCLUSIONS: In our study, haloperidol was the main pharmacological agent used for delirium in adult patients regardless of delirium subtype. Benzodiazepines, other anti-psychotics and dexmedetomidine were other frequently used agents. Haloperidol use was not statistically significantly associated with increased 90-day mortality.
AB - PURPOSE: We assessed the prevalence and variables associated with haloperidol use for delirium in ICU patients and explored any associations of haloperidol use with 90-day mortality.METHODS: All acutely admitted, adult ICU patients were screened during a 2-week inception period. We followed the patient throughout their ICU stay and assessed 90-day mortality. We assessed patients and their variables in the first 24 and 72 h in ICU and studied their association together with that of ICU characteristics with haloperidol use.RESULTS: We included 1260 patients from 99 ICUs in 13 countries. Delirium occurred in 314/1260 patients [25% (95% confidence interval 23-27)] of whom 145 received haloperidol [46% (41-52)]. Other interventions for delirium were benzodiazepines in 36% (31-42), dexmedetomidine in 21% (17-26), quetiapine in 19% (14-23) and olanzapine in 9% (6-12) of the patients with delirium. In the first 24 h in the ICU, all subtypes of delirium [hyperactive, adjusted odds ratio (aOR) 29.7 (12.9-74.5); mixed 10.0 (5.0-20.2); hypoactive 3.0 (1.2-6.7)] and circulatory support 2.7 (1.7-4.3) were associated with haloperidol use. At 72 h after ICU admission, circulatory support remained associated with subsequent use of haloperidol, aOR 2.6 (1.1-6.9). Haloperidol use within 0-24 h and within 0-72 h of ICU admission was not associated with 90-day mortality [aOR 1.2 (0.5-2.5); p = 0.66] and [aOR 1.9 (1.0-3.9); p = 0.07], respectively.CONCLUSIONS: In our study, haloperidol was the main pharmacological agent used for delirium in adult patients regardless of delirium subtype. Benzodiazepines, other anti-psychotics and dexmedetomidine were other frequently used agents. Haloperidol use was not statistically significantly associated with increased 90-day mortality.
U2 - 10.1007/s00134-018-5204-y
DO - 10.1007/s00134-018-5204-y
M3 - Journal article
C2 - 29767323
VL - 44
SP - 1081
EP - 1089
JO - European Journal of Intensive Care Medicine
JF - European Journal of Intensive Care Medicine
SN - 0935-1701
IS - 7
ER -
ID: 197811680